Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses
Once-weekly (OW) subcutaneous semaglutide is a GLP-1RA supported for the treatment of type 2 diabetes (T2D) at dosages of 0.5 mg and 1.0 mg. The study reflected that OW semaglutide portrayed superior reduction in HBA1c levels along with weight loss compared to other GLP-1Ras. John. B. Buse and colleagues conducted a research titled “Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses”. The summary of this research is given below:
Objectives:
The primary treatment objective was to establish the predominant impact of OW subcutaneous semaglutide 2.0 mg versus 1,0 mg on glycaemic control in members with T2D on metformin ± SU treatment while the secondary objective was to observe and compare the effect of both dosages on body weight, vital signs and general safety and tolerability.
Method:
The study was a randomized double-blind phase 3b trial researching the viability and safety of the OW semaglutide (2 mg vs 1 mg) in 961 adults having T2DM needing intensive therapy in a 40-week period on a dose of metformin ± sulphonylurea.
Findings:
A greater decrease in HBA1c and an additional reduction in body weight was observed in Semaglutide 2.0 mg versus semaglutide 1.0 mg. Efficacy of Semaglutide 2.0 mg was greater than 1.0 mg dosage and had same safety profile.
Limitations:
Less than 5% of the participants discontinued training due to gastrointestinal events.
Image Credit : Background photo created by xb100 – www.freepik.com
